Anna Anschlag1, Brandon H Greene2, Lorianna KÖnneker3, Markus Luster4, James Nagarajah5, Sabine WÄchter6, Annette Wunderlich6, Andreas Pfestroff4. 1. Department of Child and Adolescent Psychiatry, University Hospital of Marburg, Marburg, Germany; anschlaa@staff.uni-marburg.de. 2. Bio 21 Institute, CSL Limited Melbourne, Parkville, VIC, Australia. 3. Department of Virology, Hospital Nordwest Frankfurt, Frankfurt, Germany. 4. Department of Nuclear Medicine, University Hospital of Marburg, Marburg, Germany. 5. Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany. 6. Department of Visceral, Thoracic and Vascular Surgery, University Hospital of Marburg, Marburg, Germany.
Abstract
BACKGROUND/AIM: We evaluated the potential of the kinase inhibitors sorafenib, lenvatinib and selumetinib on increasing the uptake of technetium-99m into thyroid cancer cells. MATERIALS AND METHODS: Four established cell lines and three patient's cell cultures were treated with 0.1, 1 and 5 μM of sorafenib, lenvatinib and selumetinib for 72 hours. After incubation with 1 MBq of technetium-99m, the radioactivity uptake was measured. RESULTS: The experiments showed heterogeneous results. Maximum technetium-99m uptake increases of 312% (sorafenib), 326% (lenvatinib) and 759% (selumetinib) were obtained using the highest applied concentrations. In some tests, an uptake reduction or no effect was observed. CONCLUSION: Kinase inhibitors have a positive effect on technetium-99m uptake. Due to study limitations, a redifferentiating effect of the drugs could not be definitely proven. Unspecific cytotoxicity might have a confounding effect. Copyright
BACKGROUND/AIM: We evaluated the potential of the kinase inhibitors sorafenib, lenvatinib and selumetinib on increasing the uptake of technetium-99m into thyroid cancer cells. MATERIALS AND METHODS: Four established cell lines and three patient's cell cultures were treated with 0.1, 1 and 5 μM of sorafenib, lenvatinib and selumetinib for 72 hours. After incubation with 1 MBq of technetium-99m, the radioactivity uptake was measured. RESULTS: The experiments showed heterogeneous results. Maximum technetium-99m uptake increases of 312% (sorafenib), 326% (lenvatinib) and 759% (selumetinib) were obtained using the highest applied concentrations. In some tests, an uptake reduction or no effect was observed. CONCLUSION: Kinase inhibitors have a positive effect on technetium-99m uptake. Due to study limitations, a redifferentiating effect of the drugs could not be definitely proven. Unspecific cytotoxicity might have a confounding effect. Copyright
Authors: Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit Journal: Eur Thyroid J Date: 2019-08-28
Authors: E N Klein Hesselink; D Steenvoorden; E Kapiteijn; E P Corssmit; A N A van der Horst-Schrivers; J D Lefrandt; T P Links; O M Dekkers Journal: Eur J Endocrinol Date: 2015-01-08 Impact factor: 6.664
Authors: Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman Journal: N Engl J Med Date: 2015-02-12 Impact factor: 91.245
Authors: Hendrieke Hoftijzer; Karen A Heemstra; Hans Morreau; Marcel P Stokkel; Eleonora P Corssmit; Hans Gelderblom; Karin Weijers; Alberto M Pereira; Maya Huijberts; Ellen Kapiteijn; Johannes A Romijn; Johannes W Smit Journal: Eur J Endocrinol Date: 2009-09-22 Impact factor: 6.664
Authors: Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544